Introducing PRISM by Chirasoph
Promising Drug Candidate.
Investable Asset.
The execution liabilities aren’t always visible.
Change that with PRISM — Chemistry, Manufacturing & Controls risk, decoded before Phase II.
Technical and production complexities break promising therapeutics long before they reach clinical benchmarks. Most are assessable pre-Phase II — yet routinely missed during due diligence. PRISM provides structured, predictive intelligence into early-stage evaluations — surfacing overlooked development execution risks before capital is committed.
THE PROBLEM
Most failures are
preventable — if you
know where to look.
Developability, manufacturing readiness, capacity alignment, and supply chain resilience are consistently missed in early candidate evaluation. By the time these risks surface, the cost of failure has already compounded.
PRISM was built to change that.
PRISM focuses on the window where it matters most — before Phase II, where manufacturing risk is fully assessable, the decisions are still reversible.
90%
drugs fail in clinical trial.
50%
of failures are linked to risks that were present — and assessable — before Phase II.
$1B+
average total cost to bring a drug to market.
THE TOOL
PRISM — Pipeline Risk Intelligence & Structured Mapping
Pipeline Risk Intelligence & Structured Mapping
01
Candidate Viability
Structural liability mapping, formulation strategy, production compatibility across the candidate’s intrinsic profile.
02
Manufacturing Viability
Scale-up mechanics, process safety, formulation feasibility, analytical readiness, production economics and early regulatory alignment.
03
Capacity Readiness
Clinical supply projections, CDMO capacity, tech transfer readiness, and alignment of production timelines to trial milestones.
04
Supply Assessment
Starting material sourcing, vendor qualification, single-source risk flags, geopolitical exposure, and backup supplier strategy.
WHO IT’s FOR
Built for the people
making high-stakes decisions
Investors & VCs
Due diligence teams
Rapidly assess technical risk in pre-Phase II portfolios guided through a structured framework that surfaces the questions that matter before capital is committed.
Biotech Leaders
Leadership teams
Understand the manufacturability and supply risks of your lead candidates early — strengthening your investor narrative and bringing rigour to your go/no-go decisions.
BD & Licensing
External innovation
Evaluate in-licensing opportunities through a structured, expert-guided risk framework — before entering term sheets or committing to partnership negotiations.
FOUNDATION
“PRISM is built from failures — real development programmes, real FDA outcomes, and the patterns that emerge when you look at both together.”
METHOD
400+
Grounded in regulatory outcome data and direct development experience — and designed to evolve as the data does.
PILLARS
4
Four evaluation dimensions — each built around the decision points that determine whether a programme advances or stalls.
FOCUS
Pre-Phase II
The highest-leverage point of intervention — before Phase II, when course corrections are still possible and the cost of getting it right is a fraction of the cost of getting it wrong.
EARLY ACCESS
PRISM is coming.
Be among the first to use it.
We are currently working with a select group of partners — investors, founders, and BD teams — to bring it to life. If you’re evaluating pre-Phase II therapeutic assets and want to be among the first to access structured, expert-guided risk intelligence — register your interest below.
We will not share your details. No spam, ever.